Can Semax help with autism?
There are no direct studies on Semax and the autism spectrum. There are no clinical trials. There are also no animal models specifically designed to study autism. And no published research at all connects the two topics.
It's worth stating this clearly at the outset. It's easy to come across Semax discussed alongside autism online and assume there's some scientific basis for it. Based on available research, there simply isn't. Nothing in the literature analyzes Semax's effects specifically in autism, in animal models of autism, or in any way that would allow us to answer this question with actual evidence.
What evidence exists for Semax and autism?
Since there are no direct studies on autism, a reliable answer requires a different approach. We can examine whether the known mechanisms of Semax have any theoretical relevance to brain differences associated with autism. However, we must be very careful not to overstate what this theoretical relevance actually means.
The best-documented mechanism of Semax is a strong increase in BDNF and NGF, growth factors that support neuronal development, synaptic connectivity, and neuroplasticity [1], [2]. Studies outside the Semax literature have analyzed the role of BDNF in various neurodevelopmental conditions. Some researchers have investigated whether differences in BDNF signaling play a role in autism.
But the combination of „Semax increases BDNF” with „Semax may help with autism” requires several unproven leaps of logic. First, that BDNF differences significantly contribute to autism symptoms in a way sometimes hypothesized. Second, that externally increasing BDNF would significantly correct those differences. Third, that this would translate to a beneficial, rather than neutral, or even harmful effect on autism-related traits specifically. None of these leaps have been tested.
Other documented properties of Semax also touch upon significant biological territory. These include effects on GABA and glutamate receptor systems [3], modulation of serotonin and dopamine activity [4], and anti-inflammatory effects on gene expression [5]. All of these systems have been studied separately in broader autism research. But touching the same general biological territory as a given condition is very different from having evidence that a compound actually helps with that condition. It would be misleading to present this kind of mechanistic overlap as anything more than a starting point for an untested hypothesis.
Is Semax safe in the autism spectrum?
Since there is no research on Semax in autism, there is also no safety data specific to this population. This is of greater importance than it might be for some other investigational uses. The autism spectrum includes significant individual variability in neurological function. Some individuals with autism have co-occurring conditions, such as epilepsy, much more frequently than the general population. Semax has been associated with EEG changes in at least one clinical population — patients recovering from hypoxic injury [6]. Given this, and considering the complete lack of safety data in autistic individuals of any age, using Semax in this population would mean proceeding essentially without any significant safety information to rely upon.
What are parents and users reporting about Semax for autism?
Anecdotal reports regarding Semax and autism circulate in some online communities of parents and caregivers. However, these reports are entirely beyond anything that can be scientifically evaluated. Parents observing their children may understandably have a strong desire to find something that helps. This can make it truly difficult to distinguish a real effect from natural developmental changes, other concurrent interventions, or the very human tendency to notice and remember improvements more than noticing a lack of change. None of this is meant to discount what any family has experienced. However, it's important to honestly acknowledge that these reports cannot substitute for actual research. Currently, none exist for this specific application.
What would real research on Semax for autism look like?
If it were ever formally investigated, it would require several things. Properly designed studies with autistic participants. Appropriate autism-specific outcome measures. Careful safety monitoring, given the unique needs of this population. And comparison to a placebo. Nothing resembling that has been done.
Given the complete lack of research, Semax currently cannot be recommended, cautioned against, or significantly discussed as an intervention for autism based on anything more than speculation.
Is Semax safe for teenagers?
No study has been performed specifically analyzing the safety or effects of Semax in adolescents. This lack of data is a true and relevant gap, not a minor technicality. Adolescence is a period of significant ongoing brain development. Neural circuits are still actively being wired and pruned during this time. Introducing a compound that significantly alters neurotrophic factor levels and neurotransmitter activity during this developmental window has simply not been studied. There is no way to responsibly extrapolate adult data—already meager—to the developing adolescent brain.
Existing studies in animal neonates actually reinforce this caution rather than alleviate it. Semax administered to very young rats during critical developmental windows induced lasting changes in adult behavior, anxiety levels, and even the number of certain neurons in the brain [7], [8]. These findings tell us something important. Semax can indeed shape brain development when administered during sensitive periods. That is precisely why its use in still-developing adolescents, without any dedicated safety studies in this age group, cannot be responsibly recommended.
Can women use Semax?
Available clinical trials on humans concerning Semax have included women as participants. For instance, in a stroke recovery study involving 110 patients, 67 participants were women [9]. Therefore, there is no specific documented barrier for women's use based on sex differences reported in the literature.
However, no study has specifically analyzed whether the effects or safety profile of Semax differs significantly between men and women. Any gender-specific nuances have simply not been directly investigated.
One area worth particular mention is pregnancy. A few animal studies have actually tested Semax in pregnant rats. These studies examined its effects on offspring following maternal exposure to hypoxia — that is, a lack of oxygen during pregnancy. Generally, protective effects were found on the developing fetus in these specific contexts of stress correction [10], [11]. However, these studies were designed to test if Semax could correct damage caused by a separate stimulus, namely hypoxia. They were not designed to establish that Semax itself is safe for use during human pregnancy for general purposes. No human pregnancy safety data exists at all. Pregnant or breastfeeding women should not interpret these animal correction studies as evidence of general safety for voluntary use during pregnancy.
Is Semax safe for older adults?
Clinical studies of stroke that provide the strongest evidence base for Semax specifically included older patients. Ischemic stroke disproportionately affects older adults, so this makes sense. The average age in a study of 110 stroke patients was 58 years [9]. A study of cerebrovascular insufficiency in 187 patients specifically noted good tolerance, including in older age groups. Only a small percentage of adverse effects were reported across the entire study population [12]. This is truly reassuring. This means Semax has a genuine history of clinical use in older adults, including those with significant cerebrovascular disease—a more medically complex population than healthy younger adults.
However, this data comes from patients treated for a specific medical condition under clinical supervision. It does not come from healthy older individuals voluntarily using Semax for general cognitive support. These two situations are not identical.
Is Semax safe for people with pre-existing medical conditions?
It heavily depends on which state you're considering. The honest answer for most states is that dedicated trials simply don't exist. For individuals with a history of seizures or epilepsy, additional caution is warranted. This stems from documented EEG changes in at least one patient population [6]. For individuals with bleeding disorders or on blood-thinning medications, there is a real, mechanistically justified reason for concern. Semax has documented anti-platelet and anti-clotting effects—meaning it reduces blood clotting [13]. This is not merely a generic „be cautious with everything” warning.
For individuals with diabetes or metabolic disorders, studies show that Semax affects blood cholesterol and fat levels [14], [15]. These individuals should be aware that metabolic effects may occur which are worth discussing with a doctor. For most other chronic diseases—autoimmune diseases, kidney diseases, liver diseases beyond specific tested stress models—there are simply no studies analyzing whether Semax is safe in this context. The responsible position is to acknowledge this gap, rather than to assume safety by default.
Who should not use Semax?
Based on everything discussed above, several groups should exercise the greatest caution. Some should avoid Semax entirely without direct medical guidance. This includes pregnant and lactating women, considering the complete lack of human pregnancy safety data. This includes children and adolescents, considering the concern for ongoing brain development and the complete lack of pediatric safety studies. This includes individuals with seizure disorders, considering EEG findings in at least one population. This includes individuals taking anticoagulant medications or with clotting disorders, considering Semax's own anti-clotting properties. And this includes anyone with a known hypersensitivity to peptide compounds generally.
This is not a list built on formal contraindications from a regulatory body. Semax has not undergone that kind of formal review in Western markets. This is a list built from a careful reading of what the actual research says and doesn't say, applied with reasonable caution.
Can Semax help with bipolar disorder?
No studies have analyzed Semax in individuals with bipolar disorder. This is an area where caution is particularly warranted, considering what we know about the compound's pharmacological profile. Semax has documented dopamine-potentiating effects. It does not directly release dopamine on its own. However, it significantly amplifies the dopaminergic response to other stimuli [4], [16]. Bipolar disorder, particularly the manic phase, is closely linked to dysregulated dopaminergic signaling. There is a real, biologically plausible concern here. A compound that potentiates dopaminergic responses could theoretically destabilize mood in someone prone to mania. However, this has never actually been tested.
There is something else to consider. Semax also exhibits serotonergic activation [4] and antidepressant-like effects documented in animal models of stress [17]. These properties are already known, in the context of conventional antidepressant drugs, to occasionally induce manic episodes in individuals with underlying bipolar disorder. Taken together, there exists a plausible pharmacological reason for actual caution—not just a generalized „we don't know” disclaimer.
Is Semax safe for bipolar disorder?
Given the complete lack of research, and considering the theoretically concerning overlap of Semax's dopaminergic and serotonergic effects with known mood-destabilizing pathways in bipolar disorder, this is a population in which the use of Semax should not be considered without the direct involvement of a psychiatrist familiar with the individual's full clinical picture. This is not an area for self-experimentation.
Does Semax help with brain fog after COVID?
No study has directly investigated Semax for cognitive symptoms after COVID, sometimes referred to as long COVID brain fog. However, it is worth noting that the biological processes believed to underlie this type of persistent neurocognitive dysfunction are relevant here. These include ongoing low-level neuroinflammation, oxidative stress, and impaired neurotrophic support. These are precisely the kinds of processes that the documented mechanisms of Semax address in other contexts. The anti-inflammatory effects on gene expression seen in stroke studies [5], [18], and the antioxidant properties demonstrated in multiple models [19], [20], are mechanistically relevant to what we currently understand about the biology of cognitive symptoms following viral infection.
However, the mechanistic significance is not proof of efficacy for this specific condition. Until actual research is conducted in this population, any claim that Semax helps specifically with brain fog after COVID would be speculation masquerading as fact.
Does Semax help with chronic fatigue?
Similarly, no study has specifically examined Semax for chronic fatigue syndrome or general fatigue complaints. There is some indirect evidence. Semax has shown anti-hypoxic effects, improving resistance to low oxygen conditions in multiple animal studies [21], [22]. It has also shown protective effects on liver function and decreased markers of stress-related organ dysfunction [23]. Fatigue has many possible underlying causes. Some documented effects of Semax do touch upon processes relevant to certain fatigue mechanisms, such as cellular oxygen processing and stress hormone regulation. However, there is no direct evidence linking Semax to significant improvement in chronic fatigue as a defined clinical condition.
In which other states could Semax theoretically be beneficial?
Looking at everything documented in research, Semax's effects extend to truly unexpected corners of physiology beyond the brain. It has shown protective effects on the gastric mucosa against ulcers [24]. It supports healthy gut bacteria populations under stress [25]. It exhibits protective effects on liver cells during chronic stress [23]. It even impacts lipid metabolism, crucial for conditions like metabolic syndrome and psoriasis—adding Semax to standard treatment improved cholesterol markers in one clinical trial [15]. It has also demonstrated cardioprotective properties post-myocardial infarction in animal models, reducing harmful sympathetic nervous system overactivity and helping preserve cardiac muscle structure [26], [27].
None of these constitute the primary, well-established use of Semax. These are secondary findings scattered across a really broad research program. However, they illustrate something important. The biological reach of Semax extends far beyond the brain-focused nootropic reputation for which it is most famous.
What are the actual established uses of Semax?
Stepping back from all the speculative and off-label territory, it’s worth being clear about where the evidence for Semax is truly robust. Stroke treatment and rehabilitation. Cerebrovascular insufficiency. And, to a lesser extent, optic nerve disease. These represent uses with actual human clinical trial support [9], [12], [28]. They are also the only conditions for which Semax is actually approved and clinically used, specifically in Russia.
Everything else discussed in this article — autism, ADHD, bipolar disorder, post-COVID symptoms, chronic fatigue — falls into a completely different category. These are theoretical extrapolations from known Semax mechanisms, not demonstrated clinical benefits for these specific conditions. Being honest about this distinction is important. The gap between „this mechanism seems relevant” and „this compound has been shown to help with this condition” is exactly where exaggerated claims typically creep in. It is a gap worth respecting.
Disclaimer
This content is for educational and informational/scientific purposes only. It should not be interpreted as medical advice, diagnosis, or treatment recommendation. Semax remains a research compound in most countries, including the United States and most European countries. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) to treat any medical condition. It is approved and clinically used in Russia and some Eastern European countries, specifically for ischemic stroke, cerebrovascular insufficiency, and optic nerve disease. There are no studies on Semax for autism, bipolar disorder, post-COVID symptoms, chronic fatigue, or use in adolescents. Any individual with a diagnosed medical or psychiatric condition should consult with a qualified healthcare professional before considering Semax and should not alter, discontinue, or substitute any prescribed treatment without medical guidance. Pregnant or breastfeeding women, children, and adolescents should not use Semax outside of formal medical supervision due to a complete lack of safety data in these populations.
References
[1] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[3] Sharonova, I. N., Bukanova, Yu. V., Myasoedov, N. F., & Skrebitsky, V. G. (2018). Modulation of GABA- and glycine-activated ionic currents with Semax in isolated cerebral neurons. Bulletin of Experimental Biology and Medicine, 164(5), 612–616. https://doi.org/10.1007/s10517-018-4043-8
[4] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[5] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
Alekseeva, G. V., Bottaev, N. A., & Goroshkova, V. V. (1999). Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesthesiology and Resuscitation, (1), 40–43. PMID: 10199046
[7] Sebentsova, E. A., Denisenko, A. V., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2005). Long-lasting behavioral effects of chronic neonatal treatment with ACTH (4-10) analogue semax in white rat pups. Journal of Higher Nervous Activity named after I. P. Pavlov, 55(2), 213–220. PMID: 15895862
[8] Boyarshinova, O. S., Revishchin, A. V., Poletaeva, I. I., & Korochkin, L. I. (2004). Neonatal administration of ACTH4-10 and its analog Semax to young laboratory mice modulates the number of catecholaminergic neurons in adult animal diencephalon. Doklady Biological Sciences, 396, 181–183. https://doi.org/10.1023/b:dobs.0000033270.71306.3d
Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Maslova, M. V., Graf, A. V., Samoilenkova, N. S., Maklakova, A. S., Sokolova, N. A., & Andreeva, L. A. (2003). Consequences of progestational hypoxia in pregnant rats and its peptide correction (EEG data). Bulletin of Experimental Biology and Medicine, 135(6), 526–529. https://doi.org/10.1023/a:1025404713480
Maslova, M. V., Zemlyanskii, K. S., Shkol’nikova, M. V., Maklakova, A. S., Krushinskaya, Y. V., Sokolova, N. A., & Ashmarin, I. P. (2001). Peptidergic correction of the effect of acute hypobaric hypoxia in pregnant rats on progeny. Bulletin of Experimental Biology and Medicine, 131(2), 109–112. https://doi.org/10.1023/a:1017515206152
Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[13] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[14] Elagina, A. A., Lyashev, Yu. D., Lyashev, A. Yu., Pronyaeva, T. V., & Chahine, A. R. (2020). Correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Bulletin of Experimental Biology and Medicine, 168(5), 618–620. https://doi.org/10.1007/s10517-020-04764-2
Dontsova, E. V. (2015). Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Experimental and Clinical Pharmacology, 78(12), 30–33. PMID: 27051926
[16] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
[17] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
[19] Bashkatova, V. G., Koshelev, V. B., Fadyukova, O. E., Alexeev, A. A., Vanin, A. F., Rayevsky, K. S., Ashmarin, I. P., & Armstrong, D. M. (2001). Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Research, 894(1), 145–149. https://doi.org/10.1016/s0006-8993(00)03324-2
[20] Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[21] Iasnetsov, Vik. V., & Voronina, T. A. (2010). Antihypoxic and antiamnesic effects of mexidol and semax. Experimental and Clinical Pharmacology, 73(4), 2–7. PMID: 20486550
[22] Kaplan, A. Ya., Koshelev, V. B., Nezavibat’ko, V. N., & Ashmarin, I. P. (1992). Increased resistance to hypoxia effected by the neuropeptide preparation SEMAX. Human Physiology, 18(5), 104–107. PMID: 1335426
[23] Ivanov, A. V., Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Andreeva, L. A., & Myasoedov, N. F. (2017). Influence of ACTG4-7-PGP (Semax) on the morphofunctional state of hepatocytes under chronic emotional and painful stress. Bulletin of Experimental Biology and Medicine, 163(1), 105–108. https://doi.org/10.1007/s10517-017-3748-4
[24] Zhuikova, S. E., Smirnova, E. A., Bakaeva, Z. V., Samonina, G. E., & Ashmarin, I. P. (2000). Effect of Semax on homeostasis of gastric mucosa in albino rats. Bulletin of Experimental Biology and Medicine, 130(9), 871–873. PMID: 11177268
[25] Svishcheva, M. V., Mukhina, A. Yu., Medvedeva, O. A., Shevchenko, A. V., Bobyntsev, I. I., Kalutskii, P. V., Andreeva, L. A., & Myasoedov, N. F. (2020). Composition of colon microbiota in rats treated with ACTH(4-7)-PGP peptide (Semax) under conditions of restraint stress. Bulletin of Experimental Biology and Medicine, 169(3), 357–360. https://doi.org/10.1007/s10517-020-04886-7
S. A. Gavrilova, M. A. Markov, A. B. Berdalin, A. D. Kurenkova, & V. B. Koshelev. (2017). Changes in sympathetic innervation of the heart in rats with experimental myocardial infarction. Effect of Semax. Bulletin of Experimental Biology and Medicine, 163(5), 617–619. https://doi.org/10.1007/s10517-017-3862-3
[27] Gavrilova, S. A., Golubeva, A. V., Lipina, T. V., Fominykh, E. S., Shornikova, M. V., Postnikov, A. B., Andrejeva, L. A., Chentsov, Yu. S., & Koshelev, V. B. (2006). Protective effect of peptide semax on the rat heart after myocardial infarction. I.M. Sechenov Physiological Journal of Russia, 92(11), 1305–1321. PMID: 17385423
Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Ophthalmology Journal, 116(1), 15–18. PMID: 10741256